Activation of protein kinases and phosphatases at the plasma membrane often initiates agonist-dependent signalling events. In sensory neurons, AKAP150 (A-kinase-anchoring protein 150) orientates PKA (protein kinase A), PKC (protein kinase C) and the Ca 2+ /calmodulin-dependent PP2B (protein phosphatase 2B, also known as calcineurin) towards membrane-associated substrates. Recent evidence indicates that AKAP150-anchored PKA and PKC phosphorylate and sensitize the TRPV1 (transient receptor potential subfamily V type 1 channel, also known as the capsaicin receptor). In the present study, we explore the hypothesis that an AKAP150-associated pool of PP2B catalyses the dephosphorylation and desensitization of TRPV1. Biochemical, electrophysiological and cell-based experiments indicate that PP2B associates with AKAP150 and TRPV1 in cultured TG (trigeminal ganglia) neurons. Gene silencing of AKAP150 reduces basal phosphorylation of TRPV1. However, functional studies in neurons isolated from AKAP150 −/− mice indicate that the anchoring protein is not required for pharmacological desensitization of TRPV1. Behavioural analysis of AKAP150 −/− mice further support this notion, demonstrating that agoniststimulated desensitization of TRPV1 is sensitive to PP2B inhibition and does not rely on AKAP150. These findings allow us to conclude that pharmacological desensitization of TRPV1 by PP2B may involve additional regulatory components.
INTRODUCTION
Anchoring and scaffolding proteins function to target proteins to distinct subcellular environments or within distinct signalling pathways, controlling the activity of neighbouring substrates [1] . AKAP150 (A-kinase-anchoring protein 150) is a scaffolding protein that organizes the phosphorylation and/or dephosphorylation of various plasma membrane targets [2] . The human AKAP orthologue AKAP79 and the murine AKAP150 interact with multiple signalling enzymes, including PKA (protein kinase A), PKC (protein kinase C) and PP2B (protein phosphatase 2B) [3] . Specifically, anchoring of PKC and PKA via AKAP150 is necessary for the phosphorylation and sensitization of TRPV1 (transient receptor potential subfamily V type 1 channel) [4] [5] [6] . Phosphorylation of TRPV1 results in sensitization of the channel to activation by multiple pain-evoking stimuli, including noxious heat (>42
• C), acidic pH and CAP (capsaicin), the active ingredient in chilli peppers [7, 8] . Previous studies have demonstrated that truncation or mutation of the PKA-binding site of AKAP150 interferes with the phosphorylation and subsequent sensitization of TRPV1 [9] . As a consequence, the functional involvement of AKAP150 in TRPV1 phosphorylation and sensitization demonstrates a critical role for this scaffolding complex in peripheral nociception [4] .
Several investigators have demonstrated that sustained stimulation of TRPV1 leads to pharmacological desensitization of the receptor [10] [11] [12] . Dephosphorylation of TRPV1 by PP2B is a critical mechanism that leads to desensitization of the channel [13] [14] [15] [16] .
The Ca 2+ /calmodulin-dependent serine/threonine phosphatase PP2B is a heterodimeric protein composed of a 60 kDa catalytic A subunit and a 19 kDa regulatory B subunit [17] . AKAP150 contains a principle PP2B-binding site within its C-terminus (amino acids 605-647), and mutation of this site demonstrates that anchoring of PP2B to AKAP150 is necessary for the dephosphorylation of various protein targets [18, 19] .
Specificity in cell signalling can be influenced by the targeting of different enzyme combinations to substrates [18] . In the present study, we examine whether dephosphorylation and desensitization of TRPV1 in primary TG (trigeminal ganglia) neurons relies on AKAP150-mediated targeting of PP2B. This detailed investigation into AKAP150-mediated regulation of TRPV1 is necessary to understand the underlying molecular mechanisms involved in pain and nociception.
EXPERIMENTAL Tissue culture
All procedures using animals were approved by the Institutional Animal Care and Use Committee of UTHSCSA (University of Texas Health Centre at San Antonio), and were conducted in accordance with policies for the ethical treatment of animals established by the NIH (National Institutes of Health). TG neurons were dissected bilaterally from male Sprague-Dawley rats (200-250 g; Charles River Laboratories) and disassociated by treatment with collagenase (catalogue number S5K8219, Worthington) for 30 min, following by treatment with trypsin (Sigma) for 15 min. Cells were centrifuged (2000 g for 2 min at 25
• C), aspirated and re-suspended in DMEM (Dulbecco's modified Eagle's medium, Invitrogen) supplemented with 10 % FBS (fetal bovine serum, Invitrogen), 100 ng/ml nerve growth factor (Harlan Laboratories), 1 % penicillin/streptomycin (Invitrogen) and 1 % glutamine (Sigma), and then placed on poly-D-lysine-coated plates. Cultures were maintained at 37
• C and 5% CO 2 and grown for 5-7 days. CHO (Chinese-hamster ovary) cells were utilized for heterologous expression of cDNA constructs. CHO cells were maintained at 37
• C and 5% CO 2 and transfected using Lipofectamine TM 2000 (Invitrogen) following the manufacturer's instructions.
siRNA (small interfering RNA) transfection
siRNA duplexes designed to specifically knockdown AKAP150 were constructed by Thermo Scientific (Dharmacon). The sequence for the sense strand of AKAP150 siRNA used was GCAUGUGAUUGGCAUAGAA-dTd [4] . TG neurons were transfected with scrambled siRNA (Silencer-1, Ambion) or AKAP150 siRNA (750 ng of siRNA/10 cm plate) using HiPerFect (Qiagen), following the manufacturer's protocol. TG neurons were utilized for experimentation at 1 day post-transfection, as validated previously [4] .
Immunoprecipitation and Western blot analysis
For each experimental condition, cells were treated with the appropriate compounds and harvested as described previously [14] . Protein quantification of cell lysates was completed using the Bradford assay [20] (Sigma) according to the manufacturer's protocol. Following protein quantification, cleared lysates (500 μg) were immunoprecipitated with 1 μg of anti-AKAP150 (R-300, Santa Cruz Biotechnology), anti-TRPV1 (R-130, Santa Cruz Biotechnology) or anti-PP2B-B (Abcam) antiserum. Next, immunoprecipitates were resolved via SDS/PAGE (12.5 % gels), and transferred on to PVDF membrane (Millipore). Western blots were blocked in 5 % non-fat dried skimmed milk in TBS-Tw (Tris-buffered saline/Tween 20:15.35 mM Tris/HCl, 136.9 mM NaCl, pH 7.6, with 0.1 % Tween 20) and visualized using anti-AKAP150, anti-TRPV1 or anti-PP2B-B antibodies, followed by the appropriate horseradishperoxidase-conjugated secondary antisera (GE Healthcare) and ECL (enhanced chemiluminescence) detection following the manufacturer's protocol (GE Healthcare). To study TRPV1 phosphorylation, TG neurons were incubated with 1 mCi of [ 32 P]P i (PerkinElmer) for 4 h at 37
• C in phosphate-free DMEM (Invitrogen) on the day of experimentation. Crude plasma membranes were prepared for immunoprecipitation, SDS/PAGE separation and transfer following UTHSCSA radiation safety protocols. Autoradiographs were developed after 18 h exposure to blots at − 80
• C. Densitometry measurements were determined using NIH Image 1.62, with the reported pixel density = (band density) − (lane background density).
Crude plasma membrane preparation
Following homogenization by 20 strokes in a Potter-Elvehjem homogenizer in a hypotonic homogenization buffer [25 mM Hepes, 25 mM sucrose, 1.5 mM MgCl 2 and 50 mM NaCl (pH 7.2)], the cell extract was incubated on ice for 15 min and then centrifuged at 1000 g for 1 min at 4
• C to remove nuclei and non-lysed cells from the homogenate. The resulting supernatant was centrifuged at 16 000 g for 30 min at 4
• C, separating cytosolic proteins from cell membrane proteins. The pellet (crude membrane fraction) was then resuspended in 500 μl of homogenization buffer containing 1 % Triton X-100.
Electrophysiology
All recordings were made in a perforated patch voltage clamp configuration at a holding potential (V h ) of − 60 mV. Recordings and following analysis were carried out at [22] [23] [24] • C from small-to-medium sized (20-35 pF) cultured TG neurons using a MultiClamp 700B amplifier and pCLAMP 10.0 software (Axon Instruments). Data were filtered at 0.5 kHz and sampled at 2 kHz. Borosilicate pipettes (Sutter) were polished to resistances of 8-10 M in perforated patch pipette solution. If necessary, access resistance (R s ) was compensated by 40-80 % to <25 M .
All recordings were made in the presence of 2 mM Ca 2+ in external solution. SES (standard external solution) comprised 140 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM D-glucose and 10 mM Hepes (pH 7.4). The pipette solution comprised 140 mM KCl, 5 mM NaCl, 1 mM MgCl 2 and 10 mM Hepes (pH 7.3), and contained 250 mg/ml amphotericin (Sigma). Drugs were applied using a computer-controlled pressure-driven eight-channel system (ValveLink8; AutoMate Scientific). Data were analysed by one-way ANOVA, and significance is indicated by * P < 0.05, * * P < 0.01 and * * * P < 0.005.
Ca 2+ imaging
To measure intracellular [Ca 2+ ] levels, the dye fura 2 AM (fura 2 acetoxymethyl ester) (2 μM; Molecular Probes) was incubated with cells for 30 min at 37
• C in the presence of 0.05 % Pluronic ® (Calbiochem/EMD Biosciences). Fluorescence was detected with a Leica DM IRB microscope fitted with a ×20/0.8 NA (numerical aperture) fluorescence objective. Fluorescence images from 340 nm and 380 nm excitation wavelengths were collected and analysed with MetaFluor Software (MetaMorph, Web Universal Imaging). Transfected cells were identified by their GFP (green fluorescent protein) fluorescence. To assess for Ca 2+ accumulation following TRPV1 activation, CAP (capsaicin, 50 nM, Tocris Bioscience) was administered for 30 s, followed by a 3 min washout with SES buffer. For analysis of TRPV1 desensitization, repeated CAP (50 nM) applications were interrupted by SES washout for 3 min. The net change in Ca 2+ ( F340/380) was calculated by subtracting the basal F340/380 Ca 2+ amounts of accumulation from the peak F340/380 Ca 2+ accumulation achieved. Cell-permeant CAIP (calcineurin autoinhibitory peptide; EMD Biosciences) (sequence Ac-RRRRRRRRRRRGGGRMAPPRRDAMPSDA-NH 2 ) was used to treat cells at 100 mM for 30 min at 37
• C prior to experimentation.
Behavioural assay
All procedures using animals were approved by the Institutional Animal Care and Use Committee of UTHSCSA, and were conducted in accordance with policies for the ethical treatment of animals established by the NIH. On the day of experimentation, CAP was dissolved in a 20 % NMP (N-methylpyrrolidinone) solution. AKAP-knockout mice were generated as described previously [21] . Prior to the experiment, wild-type and AKAP150 −/− male C57/Bl6 mice (littermates, 5-10-weeks-old) were acclimated to both the room and testing equipment for 30 min prior to testing. For experiments evaluating CAP-induced desensitization, the right hindpaw of animals was injected with either vehicle or CAP (0.5 μg/10 μl) followed 15 min later with CAP (0.5 μg/10 μl). For experiments evaluating the effect of FK-506 on CAP-induced desensitization, the plantar surface of the right hindpaw of animals was first injected with either vehicle or FK-506 (20 μg/10 μl) followed 15 min later by the CAP administration schedule described above. NMP (20 %) was used as a control for all individual experiments. The observer assessing nociceptive behaviour was blinded to the genotype of animals and injection contents used in all experiments. CAPinduced nocifensive behaviour was assessed by recording the time spent by the animal grooming and flinching of the injected hindpaw over a 5 min period [22] . In total, n = 6-10 animals per genotype/treatment were used. All reagents used were obtained from Sigma, unless otherwise indicated.
PKA RII subunit overlay analysis
Solid-phase-binding overlays were performed following previously published protocols [23] , from freshly frozen, whole TG neurons, using 50 μg of total protein for each assay.
RESULTS AND DISCUSSION
Multiple studies have determined that pharmacological desensitization of TRPV1 is sensitive to PP2B inhibition [13] [14] [15] [16] .
Furthermore, recent studies have demonstrated that AKAP150 and TRPV1 associate in peripheral afferent neurons [4] [5] [6] 9] . Since biochemical and cell-based studies have demonstrated that AKAP150 also contains a PP2B-binding site [19, 24] , we sought to determine whether the anchoring protein, the phosphatase and TRPV1 form a ternary complex in neurons cultured from TG. Western blot detection revealed that PP2B was detected in immune complexes isolated from crude plasma membrane fractions of TG neurons with antibodies against AKAP150 or TRPV1 (Figure 1 ). Similar amounts of PP2B immunoreactivity were detected in both AKAP150 and TRPV1 immunoprecipitates. There are two possible explanations for these findings: (i) the phosphatase, anchoring protein and channel form a ternary complex, or (ii) that AKAP150 and TRPV1 both have the capacity to independently interact with PP2B. In either case, the net effect would be to maintain PP2B in close proximity to TRPV1.
The kinase-anchoring function of AKAP150 directs PKA-and PKC-mediated phosphorylation of TRPV1 and the concomitant sensitization of the ion channel's activity [4] [5] [6] . Therefore we established whether the AKAP150 signalling complex influences the phosphorylation state of TRPV1. The incorporation of [ 32 P]P i into TRPV1 was measured by autoradiography. Primary cultures of TG neurons were transfected with AKAP150-specific siRNA. Additional control experiments monitored the incorporation of [ 32 P]P i into TRPV1 in neurons transfected with scrambled oligonucleotide control. Western blot analysis with an AKAP150-specific antibody confirmed gene silencing of the anchoring protein ( Figure 2A ). Previous studies have established the specificity of this and alternate AKAP150 siRNA oligonucleotide duplexes as reagents that suppress the expression of AKAP150 in TG neurons [4] . A significant decrease in basal phosphorylation of TRPV1 as indicated by 32 P incorporation was observed following gene silencing of AKAP150 in TG neurons ( Figures 2B and  2D ). In contrast, there were no significant differences in basal TRPV1 phosphorylation levels in control samples prepared from mock-transfected neurons or those transfected with scrambled siRNA ( Figure 2D ). TG neurons were treated with the TRPV1 agonist CAP (100 nM) for 30 s to determine whether agonistdependent dephosphorylation of TRPV1 [25] requires AKAP150 expression. A significant reduction in phosphorylation was observed following CAP treatment of AKAP150 siRNA-treated neurons as compared with untreated neurons (Figures 2C and 2E) . Normalization of the basal phosphorylation values revealed no significant difference in 32 P incorporation by TRPV1 between the transfection conditions ( Figure 2F ). TG neurons transfected with AKAP150 siRNA demonstrated similar levels of PP2B activity as compared with mock-and scrambled-transfected cells (results not shown). Taken together, these results not only indicate that AKAP150 may play a role in the basal phosphorylation of TRPV1, but importantly suggest that AKAP150 is not required for CAPstimulated dephosphorylation of TRPV1.
Following the characterization of the AKAP150-specific siRNA, we sought to determine whether PP2B associates with TRPV1 directly or through AKAP150-assisted anchorage. TG neurons were cultured and transfected in a mock setting or with AKAP150-specific siRNA to knockdown expression of the scaffolding protein. Following knockdown, cultures were homogenized and crude plasma membrane fractions were subjected to co-immunoprecipitation. Results shown in Figure 3 indicate that PP2B associates with TRPV1 following CAP Phosphorylation levels of TG-transfected neurons following activation (E) were normalized with basal levels of TRPV1 phosphorylation (F). *P < 0.05, **P < 0.01, and ***P < 0.005, as determined using two-way ANOVA with Bonferroni correction. Results are representative of four independent experiments. treatment, in both the presence and absence of AKAP150 expression. These findings suggest that TRPV1 does not require AKAP150 to dynamically associate with PP2B for potential dephosphorylation events.
Next, we sought to determine whether the anchoring of PP2B to AKAP150 is critical to the pharmacological desensitization of TRPV1. CHO cells were transiently transfected with rat TRPV1 and rat AKAP150. In parallel, cells were transfected with TRPV1 and an internally deleted form of the anchoring protein AKAP150 PP2B, which is unable to anchor the phosphatase [18] . Since TRPV1 is a non-selective cation channel with a preference for Ca 2+ that is directly activated by CAP [26] , changes in TRPV1 activity were determined indirectly by fluorescent measurement of CAP-induced Ca 2+ accumulation. Cells transfected with TRPV1 demonstrated normal desensitization/tachyphylaxis upon repeated applications of CAP (50 nM), in the presence of low endogenous levels of AKAP150 expression ( Figure 4A ). CHO cells co-transfected with TRPV1 and AKAP150 ( Figures 4A and 4B ) demonstrated a similar response when compared with controls ( Figures 4A  and 4B) . Importantly, the introduction of AKAP150 PP2B failed to affect the typical CAP-mediated desensitization pattern ( Figures 4A-4C ) of TRPV1 following repeated stimulation with CAP. In Figure 4 (D), CHO cells were pre-treated with a cellpermeant CAIP to demonstrate the significant role of calcineurin across all three sets of transfected cells. These results indicate that neither AKAP150 overexpression nor AKAP150-mediated anchorage of PP2B contribute to the desensitization of TRPV1 in the heterologous CHO expression system.
More sophisticated experiments were performed in cultured neurons from wild-type and AKAP150
−/− mice. Ablation of the AKAP150 gene was demonstrated with a RII overlay assay ( Figure 5A ). Biochemical characterization confirmed that the anchoring protein was not expressed in the cell lysates of TG neurons from AKAP150 −/− mice, although surface biotinylation of TRPV1 was unaffected ( Figure 5 ). Gene silencing of AKAP150 in TG neuronal cultures supported this point, demonstrating similar levels of TRPV1 expression in plasma membrane fractions generated from mock-and AKAP150 siRNA-transfected cells ( Figure 5C ). β1-Integrin was used as a positive control for plasma membrane proteins. In order to further investigate this finding, we took a behavioural approach. Age-matched wild-type and AKAP150 −/− littermates were monitored for changes in nocifensive behaviour following the repeated administration of CAP. Injection of vehicle (20 % NMP) followed by a CAP (0.5 μg) injection in the right hindpaw of wild-type and AKAP150
−/− mice resulted in nocifensive behaviour in both groups, as determined by the time spent licking and flinching the injection site. Interestingly, AKAP150 −/− mice demonstrated a decreased response to the single CAP injection as compared with wild-type mice ( Figure 6 ). To test for CAP-specific desensitization of TRPV1, an initial injection of CAP (0.5 μg) was administered, followed by a second dose of CAP (0.5 μg) 15 min later. This resulted in decreased nocifensive behaviour in both groups ( Figure 6 ). Importantly, pre-injection of the animals with the PP2B-specific inhibitor FK-506 (20 mg/10 ml, [27] ) at the injection site reversed CAP/CAP pharmacological desensitization in both wild-type and AKAP150
−/− populations. Taken together, these behavioural results indicate that TRP agonist-mediated PP2B activation through TRPV1 drives pharmacological desensitization of TRPV1 in both wild-type and AKAP150 −/− animals. Next, we conducted electrophysiological experiments in a perforated patch-clamp configuration to detect differences in CAP/CAP pharmacological desensitization of TRPV1 in TG neurons cultured from wild-type and AKAP150 −/− animals. Normalized desensitization of TRPV1 to repeated CAP applications in the presence/absence of FK-506 or the calmodulin inhibitor W-7 were measured in multiple neurons, as illustrated in Figure 7 . Results from these studies indicate no significant differences between wild-type and AKAP150
−/− animals in normalized CAP desensitization of TRPV1, although both W-7 and FK-506 treatment reversed a significant portion and all of the desensitization in both genotypes respectively. Taken together, these results suggest that PP2B is capable of regulating the pharmacological desensitization of TRPV1 in the absence of AKAP150-assisted targeting, and that the process involves calmodulin, as other research groups have demonstrated [15, 28, 29] . Stimulation of TRPV1 by certain agonists including CAP and resiniferatoxin leads to receptor desensitization following dephosphorylation by PP2B [15, 30] . The results of the present paper elucidate the role of AKAP150 associated with PP2B in localized catalysis of CAP-induced TRPV1 desensitization. In the present study, we have demonstrated that both AKAP150 and TRPV1 associate with PP2B at the plasma membrane. Moreover, the loss of functional AKAP150 expression through siRNA-mediated gene silencing and ablation of the AKAP150 gene in mice indicated that tachyphylactic (i.e. pharmacological) desensitization of TRPV1 occurs in the absence of the scaffolding protein. This observation is supported by behavioural tests that monitor CAP-induced nociception [31] . Taken together, these results suggest that, although AKAP150 has been shown to direct the activities of PP2B with other proteins, the scaffolding protein is not required for the dynamic pharmacological desensitization of TRPV1 by PP2B.
Previous findings have implicated AKAP150 in TRPV1 desensitization [6] , although studies presented herein offer different data and an alternative explanation. In agreement with Zhang et al. [6] , we demonstrate that knockdown of AKAP150 or deletion of the PP2B-binding site in the C-terminus of −/− (KO) mice were cultured and surface biotinylated to identify plasma membrane proteins exposed to the extracellular space. (B) PKA RII subunit-binding proteins were detected in lysates generated from homogenized TGs dissected and frozen from wild-type (WT, AKAP150 +/+ ) and AKAP150 −/− (KO) mice, using 32 P-radiolabelled RIIα as a probe. Control blots indicate correct expression profiles for AKAP150 and β-actin. (C) TG neurons from rats were transfected in a mock fashion or with AKAP150-specific siRNA, and homogenates were differentially centrifuged to isolate the crude plasma membrane fraction. Equal aliquots (30 μg) of plasma membrane (PM) lysates were resolved and analysed for AKAP150, TRPV1 and β1-integrin expression. The molecular mass in kDa is indicated on the left-hand side. Arrows on the right-hand side denote immunoreactive bands of interest. Results are representative of four independent experiments. AKAP150 does not completely abolish TRPV1 desensitization. However, the utilization of AKAP150 −/− animals in behaviour and electrophysiological experiments designed to test the functional and pharmacological desensitization of TRPV1 respectively, would indicate that AKAP150 has no role in mediating PP2B-driven desensitization of the channel. Indeed, if calmodulin assists in PP2B-mediated pharmacological desensitization, as suggested previously, the N-terminal and C-terminal calmodulin-binding sites could become important tools to study the desensitization of TRPV1 [28, 32, 33] . It is also interesting that a reported 14-amino-acid AKAP150-binding site on TRPV1 [6] is located 19 residues upstream of the C-terminal calmodulin-binding site [28] . This relatively small C-terminal region that governs important intermolecular interactions with TRPV1 would certainly be subject to tight biochemical control to account for the numerous protein-protein interactions and subsequent chemical reactions that affect TRPV1 activity. Wild-type (AKAP150 +/+ ) and AKAP150 −/− mice were assessed for nocifensive behaviour as determined by time spent licking and flinching the injected hind-paw. For control experiments, both groups were injected with vehicle (20 % NMP) followed 15 min later with CAP (0.5 μg) in a 10 μl injection volume. For desensitization experiments, both groups were injected with CAP (0.5 μg/10 μl) followed by a second injection of CAP (0.5 μg/10 μl) 15 min later. FK-506 (20 mg/10 ml) was administered prior to the first CAP injection, at the same injection site. Nocifensive behaviour was recorded over a 5 min period for all experiments. **P < 0.01 and ***P < 0.005, indicates the significance from the respective genotype vehicle/CAP treatment as measured by one-way ANOVA. n = 6-10 animals/group.
One intriguing implication from our investigation is that the loss of AKAP150 significantly inhibited nocifensive responses to CAP application [34] . This evidence may suggest that AKAP150 is required for an appropriate nociceptive response in vivo following TRPV1 activation. These findings demonstrate a response to AKAP150 ablation that was not observed in heterologous CHO or cultured TG models. Previous data using thermal stimulation of peripheral nociceptors did not reveal this genetic difference [5] . This may be due to the peripheral expression of other heatsensitive channels including TRPV3 [35] and TRPV4 [36, 37] that may not be dependent upon AKAP150 scaffolding proteins for functionality in vivo. In agreement with our in vitro results, agonist-mediated behavioural desensitization still occurred in AKAP150 −/− animals, supporting the conclusion that AKAP150 does not participate in the pharmacological desensitization of TRPV1.
The results generated from the present study indicate that the expression of AKAP150 is not necessary for pharmacological desensitization of TRPV1 in TG neurons. However, the presence of AKAP150 and association with TRPV1 at the plasma membrane may be necessary for appropriate responses to typical nociceptive stimuli. Continued investigation of additional target proteins that associate with AKAP150 and/or TRPV1 may serve to elucidate additional mechanisms that underlie TRPV1 desensitization.
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